Program
lorundrostat
Also written as “lorundrostat Dose 1”, “lorundrostat Dose 2” and “Lorundrostat”.
Its studies are mostly in Hypertension · Sleep Apnea, Obstructive, led by Mineralys Therapeutics.
Furthest: phase 3, since Jul 14, 20234 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mineralys Therapeutics | 41 open or running | phase 3since Jul 14, 2023 | Feb 24, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2023First study: phase 2 study in HypertensionFirst studyNCT05769608 · 285 enrolled · United States
- Jul 14, 2023Phase 3 study in HypertensionNCT05968430 · 1,076 enrolled · United States, Australia, Bulgaria and more
- Nov 17, 2023Phase 3 study in HypertensionNCT06153693 · 1,083 enrolled · United States, Australia, Bulgaria and more
- Jan 16, 2025Phase 2 study in Sleep Apnea, ObstructiveNCT06785454 · 48 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06785454Sleep Apnea, Obstructive · United States | 2 | Completed | Dec 17, 2025 | 48 |
| NCT06153693Hypertension · United States, Australia, Bulgaria and more | 3 | Completed | Dec 10, 2024 | 1,083 |
| NCT05968430Hypertension · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | Dec 30, 2025 | 1,076 |
| NCT05769608Hypertension · United States | 2 | Completed | Jan 15, 2025 | 285 |
How it is read
Names in the registry
- “lorundrostat Dose 1”, 2 entries
- “lorundrostat Dose 2”, 2 entries
- “lorundrostat”, 1 entry
- “Lorundrostat”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, 3 studies
- Sleep Apnea, Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.